Bristol-Myers Squibb and AbbVie Gain Regulatory Approvals for New Therapies
What happened
On October 21, 2026, Bristol-Myers Squibb secured accelerated regulatory approval for a combination therapy for multiple myeloma in the United States. AbbVie also secured regulatory approvals for multiple therapies in international markets.
From fool.com
Why it matters
The need for new treatments is critical for pharmaceutical companies to maintain revenue, especially given the time pressure of patent expiration. These approvals help both companies generate commercial sales in their respective fields, including oncology and immunology.
From fool.com
Who's involved
- Bristol-Myers SquibbSecured accelerated regulatory approval for a combination therapy for multiple myeloma in the United States.
- AbbVieSecured regulatory approvals for multiple therapies in international markets.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Bristol-Myers SquibbSpeculative
Could see increased revenue from the new combination therapy for multiple myeloma.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- AbbVie's new therapy approvals strengthen Genmab partnershipAbbVie's new therapy approvals strengthen joint development partnership with GenmabLikely
- New therapies from AbbVie and BMS could challenge AstraZeneca's market positionNew approvals by competitors may increase competitive pressure on AstraZeneca.Possible
- Royalty Pharma may benefit from AbbVie's new therapy approvalRoyalty Pharma may see higher revenue from AbbVie's new therapy salesPossible
- New therapy approvals may influence Cantor Fitzgerald's ratingsCantor Fitzgerald may adjust ratings following new therapy approvalsPossible
- Eli Lilly may face pressure from new therapy approvals by rivalsEli Lilly may face increased competitive pressure from new approvals by rivalsPossible
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
AbbVie
pharmaceutical company
Related events
- Major pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- AbbVie reached an agreement for a drug in Canada.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.